Fosun Pharma

completed

Fosun Pharma Group is a leading Chinese pharmaceutical group focused on research, development, production and distribution of pharmaceutical products in China. The Group currently develops, manufactures and sells over 190 formulations and 20 different types of Active Pharmaceutical Ingredients (APIs). Its products have leading market positions in the treatment of gynecological and hepatic diseases, diabetes, and malaria. The Group has 46 production lines at 13 production sites in different parts of China including Chongqing, Guangxi, Jiangsu, Shanghai and Hebei. All of the Group’s pharmaceutical production facilities are GMP (Good Manufacturing Practice) compliant. Fosun Pharma also possesses one of the largest wholesale and retail distribution networks for pharmaceutical products in China. In 2003, Fosun Pharma made a strategic decision to acquire a 49% stake in Sinopharm Medicine Holding Co., Ltd. (Sinopharm). Sinopharm is the biggest wholesaler/retailer network in China. In major Chinese cities, such as Beijing, Shanghai and Shenzhen, Fosun Pharma and Sinopharm have a total of 1,500 pharmacies and rank among the top 3 players in each city. This project aims to support Fosun’s operating activities in the next 12–18 months.